Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

Wake Up Narcolepsy Announces Inaugural Bridging Perspectives Convening

Join Us for September’s Brown Bag Webinar – Understanding and Managing Cataplexy

Wake Up Narcolepsy Launches Second Year of Worldwide Step Up For Sleep

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Join Us for August’s Brown Bag Webinar – Navigating Communication about Invisible, Chronic Illnesses

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Narcolepsy and cardiovascular health: A big picture perspective